Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Jul 18, 2011 4:55pm

356 Views

Post# 18844220

RE: RE: management shift

"I have found that whenever there was an issue with credibility or performance the fault ALWAYS lay at the leadership's feet."

If anyone doubts the verity of the above statement, just observe the debacle in the UK over the phone hacking scandal and the stupidity going on in Washington over the debt ceiling crisis. And don't forget our own management team, 16 years (from inception) and counting.

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row